Publications

2022 Int J Mol Sci. Mar; 23(6): 3147. Hakuno S, et al. IF=5.92 | Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges
Cancers affecting the gastrointestinal system are highly prevalent and their incidence is still increasing. Among them, gastric and pancreatic cancers have a dismal prognosis (survival of 5–20%) and are defined as difficult-to-treat cancers. This reflects the urge for novel therapeutic targets and aims for personalised therapies. As a prerequisite for identifying targets and test therapeutic interventions, the development of well-established, translational and reliable preclinical research models is instrumental.
Download  Read Paper
2021 Transl Androl Urol. Nov; 10(11): 4304. Zhang Y, et al. IF=3.15 | Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare but aggressive disease. Immune checkpoint inhibitors (ICIs) have been an indispensable component for the management of advanced renal cell carcinoma, and stereotactic body radiotherapy (SBRT) has offered additional immunological effect boost for improving the treatment outcomes of the patients. This case report demonstrates the synergistic effect of ICIs and SBRT in HLRCC and the potential mechanism for the repeated SBRT-induced abscopal effect, supporting the application of SBRT to oligometastatic lesion during ICIs treatment to delay disease progression.
Download  Read Paper
2022 World J Surg Oncol. 20: 37. Hou X, et al. IF=2.75 | Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
The PDX, PDO, and PDC models are optimal humanized models currently in cancer research, which can successfully simulate the human body and clinical practice. The universalization of patient-derived models will support basic cancer research and provide additional scientific evidence for novel and effective drug development. For eventual clinical application, they will also yield more precise and reliable treatments.
Download  Read Paper
2022 Nat Commun. Feb 10;13(1):791. Chen Y, et al. IF=14.92 | Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis
Copy number alterations (CNAs) are pivotal genetic events in triple-negative breast cancer (TNBC). Here, our integrated copy number and transcriptome analysis of 302 TNBC patients reveals that gene alpha-endosulfine (ENSA) exhibits recurrent amplification at the 1q21.3 region and is highly expressed in TNBC. 
Download  Read Paper
2022 - Cell Research Feb 1 32 477–490. Xiao Y, et al. IF=25.62 | Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the polar metabolome and lipidome in 330 TNBC samples and 149 paired normal breast tissues to construct a large metabolomic atlas of TNBC.
Download  Read Paper
2022 Cancer Cell Int. 22: 41. Pan B, et al. IF=5.77 | Patient-derived xenograft models in hepatopancreatobiliary cancer
Over the past few decades, subcutaneous or orthotopic cell-derived tumour xenograft models (CDX models) have been developed to simulate distinct tumours in patients. For the past several years, the patient-derived xenograft model (PDX model) has emerged as a promising tool for translational research. In this review, we summarize the methodology, advantages/disadvantages and applications of PDX models in hepatopancreatobiliary cancer research.
Download  Read Paper
2022 Int J Med Sci. Jan 4;19(2):286-298. Liu S, et al. IF=3.74 | Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer
Pancreatic cancer (PC) is one of the most fatal and chemoresistant malignancies with a poor prognosis. The current therapeutic options for PC have not achieved satisfactory results due to drug resistance. Therefore, it is urgent to develop novel treatment strategies with enhanced efficacy. This study sought to investigate the anticancer effect of gemcitabine and XCT790, an estrogen-related receptor alpha (ERRα) inverse agonist, as monotherapies or in combination for the treatment of PC.
Download  Read Paper
2022 Front Oncol. Jan 3;11:757383. Ge Y, et al. IF =6.24 | OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis
It is estimated that 35% of gastric cancer patients appear with synchronous distant metastases—the vast majority of patients presenting with metastatic hepatic disease. How to choose the most appropriate drugs or regimens is crucial to improve the prognosis of patients. OncoVee™-MiniPDX, which was used to select drugs to guide antitumor treatment, was promising to prolong survival and improve the response rate of patients with GCLM
Download  Read Paper
2022 J Oncol. Jan 27;2022:1987705. Wang J, et al. IF=4.38 | Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model
The morbidity and mortality of gastric cancer are high in China. There are challenges to develop precise and individualized drug regimens for patients with gastric cancer after a standard treatment.  The MiniPDX® system was used to establish the MiniPDX models using specimens of patients with gastric cancer.
Download  Read Paper
2022 J Oncol Pharm Pract. Jan 24;10781552221074973. Zhu X, et al. IF=1.81 | The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer
At present, the prognosis of HER2-positive advanced gastric cancer is extremely poor, and some patients fail to benefit from first-line Herceptin treatment, thus facing difficulties in choosing second-line drugs. Here, we report a 61-year-old male patient with HER2-positive advanced gastric cancer who is primarily resistant to Herceptin and has poor therapeutic effect. MiniPDX-guided anticancer method was used to screen drugs for second-line treatment, which resulted in liquefaction and necrosis of the patient's lesions and improved liver function indicators, as well as rapid relief of the patient's clinical symptoms.
Download  Read Paper